NSC 663284（SPS8I1;DA3003-1）|cas 383907-43-5|DC Chemicals

Cas No.:	383907-43-5
Chemical Name:	NSC 663284
Synonyms:	NSC 663284;5,8-Quinolinedione, 6-chloro-7-[[2-(4-morpholinyl)ethyl]amino]-;6-Chloro-7-{[2-(morpholin-4-yl)ethyl]amino}quinoline-5,8-dione;6-chloro-7-(2-morpholin-4-ylethylamino)quinoline-5,8-dione;NSC 663284 (DA3003-1,Cdc25 Phosphatase Inhibitor II);6-Chloro-7-(2-morpholin-4-yl-ethylamino)quinoline-5,8-dione;6-Chloro-7-[[2-(4-Morpholinyl)ethyl]aMino]-5,8-quinolinedione;DA3003-1;DA-3003-1;G13464;6-Chloro-7-((2-morpholinoethyl)amino)quinoline-5,8-dione;NCGC00092289-01;CDC25 Phosphatase Inhibitor II, NSC 663284;7-N-(Aminoethyl-4-morpholino)-6-chloro-5,8-quinolinedione;6-chloro-7-{[2-(morpholin-4-yl)ethyl]amino}quinoline-5,8-dione;SMR002530674;CS-7519;383907-43-5;6-chloro-7-[2-(4-morpholinyl)ethylamino]quinoline-5,8-dione;SPS8I1;HMS3676L16;NCGC00092289-02;EX-A8020;NSC 663284, >=98% (HPLC), solid;6-Chloro-7-[[2-(4-morpholinyl)ethyl]amino]-5,8-quinolinedione;6-chloro-7-{[2-(morpholin-4-yl)ethyl]amino}-5,8-dihydroquinoline-5,8-dione;NSC 663284?;NSC-663284;DS-017054;BCP16027;HMS3268K22;NSC663284;SCHEMBL2556224;MS-24764;HY-100034;SDCCGSBI-0654266.P001;Q27163848;MFCD08276924;HMS3412L16;DTXSID50327512;AKOS024456823;CY8W2F69MW;BRD-K03109492-001-02-2;DA 3003-1;DA 3003-01;DA-3003-01;BDBM420306;CHEBI:92053;5,8-QUINOLINEDIONE, 6-CHLORO-7-((2-(4-MORPHOLINYL)ETHYL)AMINO)-;5,6-chloro-7-[[2-(4-morpholinyl)ethyl]amino]-;MLS006010693;NCI60_021732;BRD-K03109492-001-01-4;UNII-CY8W2F69MW
SMILES:	O=C(C(Cl)=C1NCCN2CCOCC2)C3=C(N=CC=C3)C1=O
Formula:	C₁₅H₁₆N₃O₃Cl
M.Wt:	321.75884
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	NSC 663284 is a Cdc25 dual specificity phosphatases inhibitor with an IC50 of 0.21 μM.
Target:	IC50: 0.21 μM (Cdc25 dual specificity phosphatase)[1]
In Vivo:	NSC 663284 inhibits the growth of subcutaneous human colon HT29 xenografts in SCID mice. After a single i.v. dose of 5 mg/kg, NSC 663284 is not detectable in plasma or tissues beyond 5 min. Following NSC 663284 treatment of tumor-bearing SCID mice, reduces glutathione concentrations in HT29 tumor are decreased to a greater extent and remained decreased for longer than the reduced glutathione concentrations in liver and kidneys[2].
In Vitro:	The Cdc25 dual specificity phosphatases have central roles in coordinating cellular signaling processes and cell proliferation. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B2, and Cdc25C with Ki values of 29, 95, and 89 nM, respectively. NSC 663284 blocks cellular Erk dephosphorylation caused by ectopic Cdc25A expression. NSC 663284 displays a strong preference for Cdc25B2 as compared with VHR or PTP1B, the relative IC50 values for Cdc25B2 are 20- and 450-fold lower than for VHR or PTP1B, respectively. NSC 663284 blocks cell proliferation and the actions of cellular cdc25a. NSC 663284 has a mean IC50 value in the NCI 60 Cell Human Tumor Panel of 1.5 (0.6 µM when cells are treated for 48 h). Most sensitive are human breast cancer MDA-MB-435 and MDA-N cells, which have IC50 values of 0.2 µM[1].
Animal Administration:	Mice: C.B.-17 SCID mice bearing HT29 human colon carcinoma xenografts are stratified into the following groups of 9-10 animals: Control, vehicle control, positive control (gemcitabine, 50 mg/kg/dose i.v.), NSC 663284 at the following doses: 2, 3 or 5 mg/kg/dose i.v.. The mice are dosed every 4 days for 6 doses, and body weights and tumor volumes are recorded twice weekly. Tumors are measured with calipers, and tumor volumes are calculated. Mice are followed for 3 weeks following the completion of the dosing to monitor tumor regrowth. In a second study, C.B.-17 SCID mice bearing MDA-MB-435 human breast cancer xenografts are stratified to the same treatment groups, except that paclitaxel at 20 mg/kg i.v. every 7 days is used as the positive control[2].
References:	[1]. Lazo JS, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J Med Chem. 2001 Nov 22;44(24):4042-9. [2]. Guo J, et al. Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284). Anticancer Res. 2007 Sep-Oct;27(5A):3067-73.

Cat. No.	Product name	Field of application
DC31079	Abarelix	Abarelix is a synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and blocks the gonadotropin releasing hormone receptor in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with prostate hypertrophy or prostate cancer, since testosterone is required to sustain prostate growth.
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC79856	EVT0185	EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor. EVT0185 is converted to a CoA thioester in the liver by SLC27A2 and interacts with the CoA-binding site of ACLY. EVT0185-CoA inhibits ACLY activity with an IC50 of 2.5 μM. EVT0185 can phenocopy the immune and antitumour effects of genetic ACLY deletion. EVT0185 can increase tumour-infiltrating B cells and chemokine CXCL13 levels. EVT0185 can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
DC79609	NCGC00685960	NCGC00685960 is a Nicotinamide N-methyltransferase (NNMT) inhibitor with an IC50 < 10  nM. NCGC00685960 has potent antitumor activity. NCGC00685960 increases H3K27 trimethylation levels in ovarian cancer cells and inhibits α-SMA expression in NNMT-expressing ovarian fibroblasts. NCGC00685960 reduces 1-MNA levels, reverses SAM and H3K27 hypomethylation and significantly impairs collagen contractility in cancer-associated fibroblasts (CAFs). NCGC00685960 can be used for cancers research.
DC79112	Simepdekinra	Simepdekinra (Compound 221) is a IL-17A modulator with IC50s ≤10  nM and 10-100 nM for IL-17A/A HEK-Blue and IL-17A/F HEK-Blue cells. Simepdekinra can be used for inflammatory diseases such as psoriasis, ankylosing spondylitis and psoriatic arthritis research.
DC78751	RSL3-NH2	RSL3-NH2 is a GPX4 inhibitor and Ferroptosis inducer. RSL3-NH2 can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
DC77831	Vicadrostat	Vicadrostat (compound 29 A) is a potent and selective inhibitor of aldosterone synthase(CYP11B2) with an IC50 of 16 nM. It exhibits potential in renal disease, diabetic nephropathy, cardiovascular diseases and fibrotic disorder research.
DC77813	Zeltociclib	Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects.
DC77784	UNC10013	UNC10013 is a SETDB1 allosteric modulator that forms a covalent bond with Cys385 in the 3TD domain, exhibiting negative allosteric regulatory activity. It has a kinact/KI value of 1.0 × 106 M-1*s-1. UNC10013 effectively disrupts SETDB1-mediated Akt methylation and holds potential value for research in cancer and neurodegenerative diseases.
DC77740	T0080	T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE−/− mice.